Evidence is presented of the existence of a substance in brain (substance B) that reverses presynaptic inhibition of evoked acetylcholine (AcCho) release. Addition of guinea pig brain synaptosomal incubation medium or whole brain extracts to assays in which 1,1-dimethyl-4-phenylpiperazinium-evoked release of [3H]AcCho from guinea pig myenteric plexus synaptosomes reversed purinergic, muscarinic, and a2-adrenergic agonist inhibition. However, the extracts did not increase basal or evoked release of AcCho. Results of chromatography on Bio-Gel P-2 of a concentrated whole brain extract suggest this factor has an Mr of 700. Substance B was resistant to boiling under acid or alkaline conditions as well as incubation with phospholipase C and various proteases; ashing, however, completely destroyed activity. This endogenous factor was also found to antagonize agonist-mediated inhibition of electrically evoked contractions of myenteric plexus-longitudinal muscle strips from the guinea pig ileum. The demonstration of substance B with its ability to reverse presynaptic inhibition of AcCho release reveals one mode of presynaptic modulation.
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The concept of presynaptic inhibition of neurotransmitter release was introduced by electrophysiologists in the 1950s (1) . The elegant studies of Dudel and Kuffler on the crayfish neuromuscular junction (NMJ) (2) and Eccles and colleagues working on spinal cord reflexes in the cat (3, 4) provided the first clear description of this phenomenon. Dudel and Kuffler proposed that presynaptic -aminobutyric acid receptors exist on nerve terminals at the crayfish NMJ, which, when activated, caused a decrease in the number of quanta of neurotransmitter released by depolarization (2, 5) . Since these pioneering studies, many laboratories have presented observations consistent with the existence of receptors on nerve terminals that either enhance or inhibit the release of neurotransmitter (6) (7) (8) (9) (10) . Our laboratory has been involved in studying the nature and function of presynaptic receptors localized to neurons of the guinea pig ileum myenteric plexus that regulate the release of acetylcholine (AcCho). We have found that synaptosomes isolated from the myenteric plexus provide a model system for the study of presynaptic receptor control of AcCho release. With this preparation we have identified four presynaptic receptors-muscarinic, nicotinic, adrenergic, and purinergic (11) (12) (13) (14) .
Recently, we have turned our attention to presynaptic receptors in brain synaptosomes, focusing initially on the actions of adenosine, a neuromodulator with broad biologic significance that is thought to exert some of its actions by means of presynaptic purinergic receptors (15, 16) . Receptor binding, tissue slice, and electrophysiological studies have provided good evidence for the existence of purinergic receptors in brain that perturb neuronal activity (17) (18) (19) (20) (21) (22) (23) . To date, convincing evidence for the existence of presynaptic adenosine receptors that modulate the release of AcCho from brain synaptosomes has been lacking, with some authors presenting negative findings (24) . These observations are consistent with the fact that we were unable to reproducibly demonstrate effects of purinergic agonists on the release of AcCho from brain synaptosomes evoked by potassium, veratridine, or ouabain. Proceeding on the assumption that electrophysiological as well as receptor binding studies accurately reflect the existence of presynaptic purinergic receptors associated with neurons in brain, we investigated the possibility that a factor(s) was present in brain synaptosomal preparations that masked the existence of presynaptic purinergic receptors on cholinergic nerve terminals. In this report, we present evidence of the existence of a neuromodulator in brain that is capable of antagonizing the inhibitory action of a variety of receptor agonists on neurotransmitter release. This factor has tentatively been assigned the name substance B (from brain).
MATERIALS AND METHODS
Neurotransmitter Release Assay. Synaptosomes (P2 fraction) isolated from guinea pig ileum myenteric plexuslongitudinal muscle strips as described (11) (25) and extracts of these synaptosomes were obtained by tissue mizing and centrifugation as described below for whole brain preparations.
Brain Extract Preparation. Whole guinea pig or rabbit brain (without cerebellum) was homogenized (glass/Teflon) in 5 vol of ice-cold distilled water; the homogenate was then tissue mized at maximal speed for 60 sec on ice using a Tekmor tissue mizer. The resulting broken cell preparation was centrifuged at 100,000 x g for 1 hr and the supernatant solution was ultrafiltered under nitrogen [50 psi (1 psi = 6.89 kPa)] through an Amicon UM-10 (10,000 Mr cutoff) filter. The clear colorless filtrate was lyophilized and stored at -20°C for future use. There was no loss of activity for at least 2 weeks. Extracts of brain prepared in this manner were reconstituted in Krebs/Ringer buffer (pH 7.4) prior to use.
Intact Longitudinal Muscle Strip Preparation. The guinea pig ileum longitudinal muscle strip preparation was prepared for recording isometric contractions as described by Paton and Zar (26) . Male Hartley guinea pigs (350-450 g) were sacrificed by cervical dislocation and the ileum, excluding the distal 10-12 cm, was removed. The longitudinal muscle layer (with the attached myenteric plexus) was gently teased away from the underlying muscle. Muscle strips (doubled-over) -5-6 cm were suspended in a 5-ml organ bath containing 5 ,uM choline and 25 mM Hepes/Krebs/Ringer buffer (pH 7.4) continuously gassed with 95% 02/5% CO2 with 0.5 g of tension applied to the muscle strip. Following equilibration for 2-3 hr, during which time the buffer within the organ bath was frequently changed, maximal contractions were elicited by electrically stimulating the tissue with square wave pulses at 10-12 V/cm with a duration of 1 msec and frequency of 0.1 Hz. Drugs examined were added directly to the organ bath and washed out by perfusion with fresh KRB buffer.
Gel Chromatography. An extract from three guinea pig brains was reconstituted by suspension in 2 ml of Krebs/ Ringer buffer containing 25 mM Hepes at pH 7.4. This suspension was added to a 1.6 x 90 cm Bio-Gel P-2 column preequilibrated with the same buffer and 4.7-ml fractions were collected at 0.5 ml/min. The column void volume was determined using bovine serum albumin and calibrated using various low molecular weight compounds that were detected either by their absorbance at 280 nm or the elution of associated radiolabel. All operations were carried out at 4°C.
Materials. (-)-PIA and adenosine deaminase were purchased from Boehringer Mannheim. Choline chloride, ATP, ATP:choline phosphotransferase (EC 2.7.1.32; choline kinase), 1,1-dimethyl-4-phenylpiperazinium (DMPP) iodide, tetraphenylboron, Hepes, and phospholipase C were obtained from Sigma. Formula 
RESULTS
The existence of a factor that reverses receptor-activated inhibition of AcCho release was observed in experiments in which incubation medium from guinea pig brain synaptosomes was added to assays in which the effect of the purinergic agonist (-)-PIA on the release of labeled AcCho from myenteric plexus synaptosomes was examined. When the supernate obtained following centrifugation to remove the synaptosomes was added to these assays, inhibition of DMPP-evoked AcCho release produced by 10 ,M (-)-PIA was completely reversed, whereas the evoked release of
[3H]AcCho was unaffected (Table 1) . Subsequently, using an extract prepared from whole brain, the inhibition of DMPPevoked release of [3H]AcCho from ileal synaptosomes occurring in the presence of the muscarinic agonist oxotremorine (100 AM), the purinergic agonist (-)-PIA (10 MM), and the adrenergic agonist clonidine (100 MM) was dramatically antagonized (Fig. 1) . With this preparation it was necessary to use an unusually high concentration of clonidine. In subsequent experiments using the intact ileal strips as a bioassay, 100 nM clonidine was sufficient to inhibit electrically stimulated contractions and this inhibition was reversed by the addition of substance B (27) . Extracts prepared from rat and guinea pig brain synaptosomes purified on sucrose gradients as well as extracts from whole rabbit brain were also found to reverse presynaptic inhibition. Extracts alone did not result in an increase in either basal or evoked release of [3H]AcCho.
To effect a more efficient and less laborious assay for this endogenous neuromodulator (substance B), a more classical approach was taken whereby the intact guinea pig ileal longitudinal muscle strip preparation was employed. The results of experiments in which the effect of increasing concentrations of whole brain extracts on the inhibition by 200 nM 2-chloroadenosine of electrically evoked contractions are shown in Fig. 2 . Addition of brain extracts alone did not have a significant effect on the force of concentrations, whereas increasing concentrations of the brain extract added to the tissue bath resulted in a concentration-dependent reversal of inhibition produced by the purinergic agonist. It should be noted that desensitization to the inhibitory effect of 2-chloroadenosine does not occur over this same period. Since results of studies conducted in our laboratory and that of others have shown that purinergic agonists affect electri- cally evoked AcCho release from guinea pig ileum longitudinal muscle strips (28) , it is likely that the reversal of inhibition of contraction caused by 2-chloroadenosine reflects the disinhibition of AcCho release from the intact tissue preparation and corroborates our findings using synaptosomes. Fig. 3 illustrates the results of experiments in which some of the chemical properties of the endogenous modulator were investigated. Substance B was not inactivated by boiling for 30 min at neutral pH or at either pH 1.0 or 12.5. Treatment with the enzymes Pronase, trypsin, and phospholipase C did not destroy the ability of the brain factor to reverse inhibition of contraction produced by 200 nM 2-chloroadenosine. However, complete loss of activity occurred upon ashing. Preliminary experiments indicate that this factor remains at the origin on paper electrophoresis (pH 5.3, 3 mA per strip, 2 hr) and is not retained on charcoal, ion-exchange resins, or tuBondapak C18 reverse-phase HPLC with 0.1% trifluoroacetic acid as the mobile phase. On TLC or paper chromatography, it migrates only with highly polar media. It is probably not a sugar since preincubation with periodate does not inactivate it. The results of gel chromatography of whole guinea pig brain extract shown in Fig. 4 suggest that this endogenous neuromodulator has an approximate Mr of 700, assuming no interaction of the column with the factor. Acid hydrolysis (6 M HCl, 24 hr) of the partially purified preparation and subsequent amino acid analysis indicated the presence after hydrolysis of large amounts of glutamate and a trace of glycine. Whether this peptide represents substance B or a contaminant in the preparation remains to be determined.
DISCUSSION
The identification of the endogenous neuromodulator tentatively referred to as substance B (from brain), which antagonizes presynaptic modulation, probably accounts for the difficulties encountered in our laboratory as well as that of others in consistently observing presynaptic modulation of AcCho release from brain, particularly synaptosomal preparations. Marchi et al. (29) have observed evidence of presynaptic muscarinic receptor-mediated inhibition of AcCho release using a superfused brain synaptosome preparation. An unexplained outcome of their study, however, was the observation that although striatum demonstrated the highest [3H]choline uptake and AcCho synthesis of the brain areas examined, evidence for autoreceptor regulation of continuously gassed with 95%02/5% CO2 and maintained at 370C. Contractions were stimulated by square wave pulses at 10 V/cm with a duration of 1 msec and a frequency of 0.1 Hz. Lyophilized guinea pig whole brain extract was resuspended in the same buffer to give a 3.5-fold concentrate and increasing volumes were added to the organ bath. Gel chromatography of guinea pig brain extract. Lyophilized extract from three guinea pig brains was suspended in 2 ml of KRB buffer containing 25 mM Hepes at pH 7.4. This suspension was added to a 1.6 x 90 cm Bio-Gel P-2 column preequilibrated in the same buffer and 4.7-ml fractions were collected at 0.5 ml/min and at 4°C. The column void volume was determined using bovine serum albumin and calibrated (see Inset) using various low molecular weight compounds that were detected either by their absorbance at 280 nm or the elution of associated radiolabel. Fractions containing substance B were assayed by addition of aliquots to guinea pig ileum myenteric plexus-longitudinal muscle preparation assay. The results are expressed as the percent reversal of inhibition of electrically stimulated contractions produced by 200 nM 2-chloroadenosine.
AcCho release was disappointing, with effects only seen at very high concentrations of agonist. Situations in which presynaptic modulation of AcCho release has been observed often require very high concentrations of receptor agonist in conjunction with low levels of stimulation of transmitter release. We have observed a functional competition between substance B and presynaptic agonist inhibition reflected by the fact that higher levels of presynaptic agonist are needed to produce inhibition in the presence of substance B. This is entirely consistent with observed effects on neurotransmitter release occurring only at greatly elevated presynaptic agonist concentrations in vitro.
Results of experiments employing the guinea pig ileum myenteric plexus synaptosomes would, at first glance, suggest that substance B is not present in these nerve endings. However, comparison of the concentrations of presynaptic receptor agonist required to inhibit the release of AcCho from the intact longitudinal muscle strip preparation and the synaptosomes derived from the myenteric plexus indicates dramatic differences. Although effects of 2-chloroadenosine on muscle contractions are observed in the nanomolar range, micromolar concentrations are required to see effects on AcCho release from synaptosomes. We have observed that the intact muscle strip preparation requires several hours to show consistent and maximal responses to inhibitory agonists and, if a fresh muscle strip is simply added to this tissue bath, reversal of inhibition by 200 nM 2-chloroadenosine is observed. These observations indicate that the myenteric plexus contains substance B but at a level not sufficient to completely block the effect of inhibitory presynaptic agonists. (In direct preliminary experiments we have found substance B in a small concentration in the ileum, a large amount in the heart, and none in kidney or liver.)
The disinhibitory action of substance B cannot simply be attributed to a general stimulation of neurotransmitter release since addition of brain extracts to assays in which the nicotinic-evoked release of AcCho was measured did not result in an increase of basal or evoked release. In fact, on occasion, the crude factor produced a slight decrease in basal and evoked release of AcCho. Further, it is clear from the results presented here that the noninhibitory action of the factor is not due to the action of substance B as a presynaptic receptor antagonist. This explanation would require that this endogenous neuromodulator be an antagonist at purinergic, muscarinic, and adrenergic presynaptic receptors and this is highly unlikely. Reversal of inhibitory presynaptic receptor action may involve effects on a second messenger system and/or ionic conductance that is common to each of the receptor systems studied. A possible mechanism, consistent with the observed biochemical correlates (30, 31) (15) . This finding also implies that release and modulation of release involve two different mechanisms. However, the ability of substance B to prevent inhibition of neurotransmitter release without directly stimulating release would be predicted if this factor antagonized the ability ofthe inhibitory G protein to affect adenylate cyclase or possibly phosphatidylinositol phosphate hydrolysis. The importance of substance B as a tool for the study of the biochemical basis for presynaptic inhibition is obvious.
In summary, this report presents evidence for the existence of a factor in brain that possesses the ability to reverse presynaptic modulation observed in synaptosomes and longitudinal muscle strips isolated from guinea pig ileum. 
